

Results of Annual General Meeting

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed clinical drug development and care delivery company, advises that its 2022 Annual General Meeting was held today, 25 October 2022. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

Poll Results

		For		Against		Abstain
Resolutions		Number	%	Number	%	Number
1	Adoption of Remuneration Report	64,586,068	99.54	300,872	0.46	273,390
2	Re-election of Matthew Callahan	105,582,917	99.97	30,000	0.03	73,012
3	Approval of issue of Director Options	64,341,068	99.14	555,872	0.86	263,390
4	Approval of 10% Placement Facility	105,302,045	99.70	320,872	0.30	63,012
5	Modification of Existing Constitution	105,377,045	99.71	305,872	0.29	3,012
6	Re-insertion of Proportional Takeover Bid Approval Provisions	105,657,917	99.98	25,000	0.02	3,012
7	Approval of New Plan	64,879,818	99.95	30,512	0.05	250,000
8	Approval of potential termination benefits under the New Plan	64,508,946	99.40	386,384	0.60	265,000

Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain
1	Adoption of Remuneration Report	61,362,368	300,872	1,963,700	273,390
2	Re-election of Matthew Callahan	102,359,217	30,000	1,963,700	73,012
3	Approval of issue of Director Options	61,117,368	555,872	1,963,700	263,390
4	Approval of 10% Placement Facility	102,078,345	320,872	1,963,700	63,012
5	Modification of Existing Constitution	102,143,345	305,872	1,973,700	3,012
6	Re-insertion of Proportional Takeover Bid Approval Provisions	102,424,217	25,000	1,973,700	3,012
7	Approval of new Plan	61,646,118	30,152	1,973,700	250,000
8	Approval of potential termination benefits under the New Plan	61,275,246	386,384	1,973,700	265,000

Release authorised by:
Simon Robertson
Company Secretary

FOR FURTHER INFORMATION

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com

Andrew Williams
Media Relations
+61 (0) 416 583 672
awilliams@emyria.com

Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au

DRUG DEVELOPMENT

CLINICAL PROGRAMS
Ultra-Pure cannabinoid delivery platform

NEW DRUG DISCOVERY

PRE-CLINICAL PROGRAM
MDMA-like analogues

EMD-RX5 "direct-to-consumer"	
Formulation optimisation	✓
Phase 1 study	✓
Ethics approved for Phase 3	✓
Phase 3 commencement	✓
Regulatory submission	
Commercial strategy Australia	
Commercial strategy Europe	
Commercial strategy USA	

EMD-RX7 "prescription medicine"	
Formulation optimisation	✓
Phase 1	
Pre-IND (FDA)	
Pivotal trials	

MDMA-like drug development	
Continuous creation & screening	✓
First patent family filed	✓
US-focussed preclinical program	✓
Metabolic studies	✓
Preclinical assays (multiple animal models)	✓
Human cell line assays	✓
Advanced assay development	
Lead selection	
Phase 1 trials	
Global commercial strategy	

ABOUT EMYRIA | emyria.com

Emyria Limited is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes in neuroscience and mental health via:

- **Drug Development:** Emyria has developed an Ultra-Pure cannabinoid platform that can support the registration of multiple proprietary dose forms. Emyria's first dose form, EMD-RX5 is in Phase 3 trials
- **New Drug Discovery:** Inspired by MDMA, Emyria is developing one of the world's largest libraries of MDMA-like compounds with partner, the University of Western Australia.
- **Proprietary Real-World Data (RWD):** Emyria gathers ethically-sourced data with patients cared for at Emyria's own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.

EMYRIA'S

[Investorhub.emyria.com](https://investorhub.emyria.com)

INTERACTIVE

Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

INVESTOR

HUB

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.